litlas
Log inCreate account

Philip J. Clements

Active 1974–2022

Also published as
PHILIP J. CLEMENTS
86
Papers
20,261
Citations
78
h-index
86
i10-index

Citations

Citations per year for Philip J. Clements1974: 4 citations1975: 9 citations1976: 4 citations1977: 1 citations1978: 8 citations1979: 9 citations1980: 2 citations1981: 13 citations1982: 14 citations1983: 5 citations1984: 5 citations1985: 13 citations1986: 11 citations1987: 7 citations1988: 6 citations1989: 10 citations1990: 10 citations1991: 14 citations1992: 12 citations1993: 10 citations1994: 18 citations1995: 10 citations1996: 32 citations1997: 24 citations1998: 21 citations1999: 21 citations2000: 23 citations2001: 31 citations2002: 43 citations2003: 61 citations2004: 44 citations2005: 45 citations2006: 74 citations2007: 101 citations2008: 75 citations2009: 113 citations2010: 93 citations2011: 113 citations2012: 93 citations2013: 71 citations2014: 105 citations2015: 132 citations2016: 171 citations2017: 138 citations2018: 160 citations2019: 750 citations2020: 706 citations2021: 618 citations2022: 460 citations2023: 271 citations2024: 484 citations2025: 185 citations2026: 4 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,313 citing papers, 21.7% of this breakdownItaly: 571 citing papers, 9.4% of this breakdownUnited Kingdom: 543 citing papers, 8.9% of this breakdownFrance: 405 citing papers, 6.7% of this breakdownGermany: 355 citing papers, 5.8% of this breakdownCanada: 272 citing papers, 4.5% of this breakdownSwitzerland: 252 citing papers, 4.1% of this breakdownJapan: 217 citing papers, 3.6% of this breakdownChina: 205 citing papers, 3.4% of this breakdownNetherlands: 204 citing papers, 3.4% of this breakdownAustralia: 149 citing papers, 2.5% of this breakdownSpain: 144 citing papers, 2.4% of this breakdown
0%21.7%Other 23.6%

Institutions

Fields

  • Medicine92.8%
  • Biochemistry, Genetics and Molecular Biology2.7%
  • Immunology and Microbiology2.3%
  • Neuroscience0.5%
  • Engineering0.3%
  • Economics, Econometrics and Finance0.2%
  • Other1.2%

Topics

  • Systemic Sclerosis and Related Diseases23.2%
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis11.4%
  • Inflammatory Myopathies and Dermatomyositis8%
  • Pulmonary Hypertension Research and Treatments3.5%
  • Multiple Sclerosis Research Studies3.3%
  • Dermatologic Treatments and Research2.7%
  • Other47.9%

Coauthors

All papers

Open in search
  1. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

    Authors: F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen, Sindhu R. Johnson, Murray Baron, Alan Tyndall, Marco Matucci‐Cerinic, Raymond P. Naden, Thomas A. Medsger, Patrícia Carreira, Gabriela Riemekasten, Philip J. Clements, Christopher P. Denton, Oliver Distler, Yannick Allanore, Daniel E. Furst, Armando Gabrielli, Maureen D. Mayes, Jacob M. van Laar, James R. Seibold, László Czirják, Virginia Steen, Murat İnanç, Otylia Kowal‐Bielecka, Ulf Müller‐Ladner, Gabriele Valentini, Douglas J. Veale, Madelon C Vonk, Ulrich A. Walker, Lorinda Chung, David H. Collier, Mary Ellen Csuka, Barri J. Fessler, Serena Guiducci, Ariane L. Herrick, Vivien Hsu, Sergio A. Jiménez, Bashar Kahaleh, Peter A. Merkel, S. Sierakowski, Richard M. Silver, Robert W. Simms, John Varga, Janet Pope - Annals of the Rheumatic Diseases 2013 cited by 3,406

  2. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

    Authors: Donald P. Tashkin, Michael D. Roth, Philip J. Clements, Daniel E. Furst, Dinesh Khanna, Eric C. Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R. Volkmann, Suzanne Kafaja, Richard M. Silver, Virginia Steen, Charlie Strange, Robert A. Wise, Fredrick M. Wigley, Maureen D. Mayes, D. Jason Riley, Sabiha Hussain, Shervin Assassi, Vivien Hsu, Bela Patel, Kristine Phillips, Fernando J. Martínez, Jeffrey A. Golden, M. Kari Connolly, John Varga, Jane Dematte, Monique Hinchcliff, Aryeh Fischer, Jeffrey J. Swigris, Richard T. Meehan, Arthur C. Theodore, Robert W. Simms, Suncica Volkov, Dean E. Schraufnagel, Mary Beth Scholand, Tracy Frech, Jerry A. Molitor, Kristin B. Highland, Charles A. Read, Marvin J. Fritzler, Grace Hyun J. Kim, Chi‐Hong Tseng, Robert M. Elashoff - The Lancet Respiratory Medicine 2016 cited by 1,062

  3. Update of EULAR recommendations for the treatment of systemic sclerosis

    Authors: Otylia Kowal‐Bielecka, Jaap Fransen, Jérôme Avouac, Mike Oliver Becker, Agnieszka Kulak, Yannick Allanore, Oliver Distler, Philip J. Clements, Maurizio Cutolo, László Czirják, Nemanja Damjanov, Francesco Del Galdo, Christopher P. Denton, Jörg H. W. Distler, Ivan Foeldvari, Kim Figelstone, M. Frerix, Daniel E Furst, Serena Guiducci, Nicolas Hunzelmann, Dinesh Khanna, Marco Matucci‐Cerinic, Ariane L. Herrick, F.H.J. van den Hoogen, Jacob M. van Laar, Gabriela Riemekasten, Richard M. Silver, Vanessa Smith, Alberto Sulli, Ingo H. Tarner, Alan Tyndall, Joep Welling, F Wigley, Gabriele Valentini, Ulrich A. Walker, Francesco Zulian, Ulf Müller‐Ladner, Thomas Daikeler, Elisabetta Lanciano, Radim Bečvář, Michal Tomcik, Ewa Gińdzieńska-Sieśkiewicz, Giovanna Cuomo, Michele Iudici, Simona Rednic, Panayiotis G. Vlachoyiannopoulos, Roberto Caporali, Patricia E. Carreira, Servicio de Reumatología, Srdan Novak, Tünde Minier, Eugene J. Kucharz, Armando Gabrielli, Gianluca Moroncini, Paolo Airo', Roger Hesselstrand, Duska Martinovic, Mislav Radić, Daniela Marasovic-Krstulovic, Yolanda Braun-Moscovici, Alexandra Balbir-Gurman, Andrea Lo Monaco, Paola Caramaschi, Jadranka Morović-Vergles, Melanie I. Čulo, Jörg Henes, Vera Ortiz Santamaria, Stefan Heitmann, Dorota Krasowska, Małgorzata Michalska-Jakubus, Matthias F. Seidel, Paul Hasler, Klinik für Rheumatologie, José A. Pereira Da Silva, Maria J. Salvador, Bojana Stamenkovic, Aleksandra Stankovic, Mohammed Tikly, Lidia P. Ananieva, Lorenzo Beretta, Gabriella Szucs, Szilvia Szamosi, Carlos de la Puente Bujidos, Servicio de Reumatología, Øyvind Midtvedt, Anna-Maria Hoffmann-Vold, David Launay, Eric Hachulla, Valeria Riccieri, Ruxandra Ionescu, Daniela Opris, Carina Mihai, Ilka Herrgott, Christian Beyer, Francesca Ingegnoli, Carlos Alberto von Mühlen, Juan José Alegre-Sancho, Emma Beltrán-Catalán, Martin Aringer, Julia Fantana and 35 more - Annals of the Rheumatic Diseases 2016 cited by 1,116

  4. Cyclophosphamide versus Placebo in Scleroderma Lung Disease

    Authors: Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel E. Furst, Edgar Arriola, Richard M. Silver, Charlie Strange, Marcy B. Bolster, James R. Seibold, D. Riley, Vivien Hsu, John Varga, Dean E. Schraufnagel, Arthur C. Theodore, Robert W. Simms, Robert A. Wise, Fredrick M. Wigley, Barbara White, Virginia Steen, Charles A. Read, Maureen D. Mayes, Ed Parsley, Kamal K. Mubarak, M. Kari Connolly, Jeffrey A. Golden, Mitchell A. Olman, Barri J. Fessler, Naomi F. Rothfield, Mark L. Metersky - New England Journal of Medicine 2006 cited by 1,667

  5. Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis

    Authors: Dinesh Khanna, Daniel E. Furst, Philip J. Clements, Yannick Allanore, Murray Baron, Lazlo Czirjak, Oliver Distler, Ivan Foeldvari, Masataka Kuwana, Marco Matucci‐Cerinic, Maureen D. Mayes, Thomas A. Medsger, Peter A. Merkel, Janet Pope, James R. Seibold, Virginia Steen, Wendy Stevens, Christopher P. Denton - Journal of Scleroderma and Related Disorders 2017 cited by 521

  6. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts

    Authors: Elizabeth R. Volkmann, Donald P. Tashkin, Myung‐Shin Sim, Ning Li, Ellen Goldmuntz, Lynette Keyes-Elstein, Ashley Pinckney, Daniel E. Furst, Philip J. Clements, Dinesh Khanna, Virginia Steen, Dean E. Schraufnagel, Shiva Arami, Vivien Hsu, Michael D. Roth, Robert M. Elashoff, Keith M. Sullivan - Annals of the Rheumatic Diseases 2018 cited by 198

  7. Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument

    Authors: Dinesh Khanna, Ron D. Hays, Paul Maranian, James R. Seibold, Ann Impens, Maureen D. Mayes, Philip J. Clements, Terri Getzug, Nihal Fathi, Amber Bechtel, Daniel E. Furst - Arthritis Care & Research 2009 cited by 247

  8. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis–Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II

    Authors: Elizabeth R. Volkmann, Donald P. Tashkin, Ning Li, Michael D. Roth, Dinesh Khanna, Anna‐Maria Hoffmann‐Vold, Grace Kim, Jonathan Goldin, Philip J. Clements, Daniel E. Furst, Robert M. Elashoff - Arthritis & Rheumatology 2017 cited by 159

  9. Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

    Authors: Suzanne Kafaja, Philip J. Clements, Holly Wilhalme, Chi‐Hong Tseng, Daniel E. Furst, Grace Hyun J. Kim, Jonathan Goldin, Elizabeth R. Volkmann, Michael D. Roth, Donald P. Tashkin, Dinesh Khanna - American Journal of Respiratory and Critical Care Medicine 2017 cited by 126

  10. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II

    Authors: Jonathan Goldin, Grace Hyun J. Kim, Chi‐Hong Tseng, Elizabeth R. Volkmann, Daniel E. Fürst, Philip J. Clements, Matthew A. Brown, Michael D. Roth, Dinesh Khanna, Donald P. Tashkin - Annals of the American Thoracic Society 2018 cited by 112

  11. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

    Authors: Otylia Kowal‐Bielecka, Robert Landewé, Jérôme Avouac, Sylwia Chwieśko, Irene Miniati, László Czirják, Philip J. Clements, Chris Denton, Dominique Farge, Kim Fligelstone, I Földvari, D E Furst, Ulf Müller‐Ladner, James R. Seibold, Richard M. Silver, Kazuhiko Takehara, B Garay Toth, Alan Tyndall, Gabriele Valentini, F.H.J. van den Hoogen, F Wigley, Francesco Zulian, Marco Matucci‐Cerinic - Annals of the Rheumatic Diseases 2009 cited by 617

  12. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

    Authors: Dinesh Khanna, Veronica J. Berrocal, Edward H. Giannini, James R. Seibold, Peter A. Merkel, Maureen D. Mayes, Murray Baron, Philip J. Clements, Virginia Steen, Shervin Assassi, Elena Schiopu, Kristine Phillips, Robert W. Simms, Yannick Allanore, Christopher P. Denton, Oliver Distler, Sindhu R. Johnson, Marco Matucci‐Cerinic, Janet Pope, Susanna Proudman, Jeffrey Siegel, Weng Kee Wong, Athol U. Wells, Daniel E. Furst - Arthritis & Rheumatology 2016 cited by 156

  13. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease

    Authors: Elizabeth R. Volkmann, Donald P. Tashkin, Michael D. Roth, Philip J. Clements, Dinesh Khanna, Daniel E. Furst, Maureen D. Mayes, Julio Charles, Chi‐Hong Tseng, Robert M. Elashoff, Shervin Assassi - Arthritis Research & Therapy 2016 cited by 86

  14. Association of Systemic Sclerosis With a Unique Colonic Microbial Consortium

    Authors: Elizabeth R. Volkmann, Yu‐Ling Chang, Nashla Barroso, Daniel E. Fürst, Philip J. Clements, Alan Gorn, Bennett E. Roth, Jeffrey L. Conklin, Terri Getzug, James Borneman, Dermot McGovern, Maomeng Tong, Jonathan P. Jacobs, Jonathan Braun - Arthritis & Rheumatology 2016 cited by 122

  15. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

    Authors: Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements, Michael D. Roth, Daniel E. Furst, Richard M. Silver, Jonathan Goldin, Edgar Arriola, Charlie Strange, Marcy B. Bolster, James R. Seibold, D. Riley, Vivien Hsu, John Varga, Dean E. Schraufnagel, Arthur C. Theodore, Robert W. Simms, Robert A. Wise, Fred Wigley, Barbara White, Virginia Steen, Charles A. Read, Maureen D. Mayes, Ed Parsley, Kamal K. Mubarak, M. Kari Connolly, Jeffrey A. Golden, Mitchell A. Olman, Barri J. Fessler, Naomi F. Rothfield, Mark L. Metersky, Dinesh Khanna, Ning Li, Gang Li - American Journal of Respiratory and Critical Care Medicine 2007 cited by 464

  16. High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease

    Authors: Jonathan Goldin, David A. Lynch, Diane C. Strollo, Robert D. Suh, Dean E. Schraufnagel, Philip J. Clements, Robert M. Elashoff, Daniel E. Furst, Sarinnapha M. Vasunilashorn, Michael F. McNitt‐Gray, Mathew S. Brown, Michael D. Roth, Donald P. Tashkin - CHEST Journal 2008 cited by 244

  17. Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II

    Authors: Elizabeth R. Volkmann, Donald P. Tashkin, Holly LeClair, Michael D. Roth, Grace Hyun J. Kim, Jonathan Goldin, Philip J. Clements, Daniel E. Furst, Dinesh Khanna - ACR Open Rheumatology 2020 cited by 55

  18. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients.

    Authors: H G Kim, Donald P. Tashkin, Philip J. Clements, Genliang Li, Matt Brown, Robert M. Elashoff, David W. Gjertson, Fereidoun Abtin, David A. Lynch, Diane C. Strollo, Jonathan Goldin - 2010 cited by 132

  19. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts

    Authors: Elizabeth R. Volkmann, Anna‐Maria Hoffmann‐Vold, Yu‐Ling Chang, Jonathan P. Jacobs, Kirsten Tillisch, Emeran A. Mayer, Philip J. Clements, Johannes R. Hov, Martin Kummen, Øyvind Midtvedt, Venu Lagishetty, Lin Chang, Jennifer S. Labus, Øyvind Molberg, Jonathan Braun - BMJ Open Gastroenterology 2017 cited by 105

  20. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo‐Controlled Trials

    Authors: Rajaie Namas, Donald P. Tashkin, Daniel E. Furst, Holly Wilhalme, Chi‐Hong Tseng, Michael D. Roth, Suzanne Kafaja, Elizabeth R. Volkmann, Philip J. Clements, Dinesh Khanna - Arthritis Care & Research 2017 cited by 81

  21. Predictive Significance of Serum Interferon‐Inducible Protein Score for Response to Treatment in Systemic Sclerosis–Related Interstitial Lung Disease

    Authors: Shervin Assassi, Ning Li, Elizabeth R. Volkmann, Maureen D. Mayes, Dennis Rünger, Binwu Ying, Michael D. Roth, Monique Hinchcliff, Dinesh Khanna, Tracy Frech, Philip J. Clements, Daniel E. Fürst, Jonathan Goldin, Elana J. Bernstein, Flavia V. Castelino, Robyn T. Domsic, Jessica Gordon, Faye N. Hant, Ami A. Shah, Victoria K. Shanmugam, Virginia Steen, Robert M. Elashoff, Donald P. Tashkin - Arthritis & Rheumatology 2020 cited by 41

  22. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

    Authors: Philip J. Clements, Peter A. Lachenbruch, Jill Siebold, Barbara White, Saul J. Weiner, Richard W. Martin, Arthur Weinstein, Michael Weisman, Maureen D. Mayes, David H. Collier - 1995 cited by 877

  23. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.

    Authors: Daniel E. Fürst, Philip J. Clements, Virginia Steen, Thomas A. Medsger, Alfonse T. Masi, William D’Angelo, Peter A. Lachenbruch, Rafael G. Grau, James R. Seibold - 1998 cited by 278

  24. Scleroderma renal crisis and renal involvement in systemic sclerosis

    Authors: Thasia Woodworth, Yossra A. Suliman, Wendi Li, Daniel E. Furst, Philip J. Clements - Nature Reviews Nephrology 2016 cited by 165